IL18 and triple-A syndrome: The IL-1β, IL-6, IL-10, IL-18, ROS and MDA levels were increased and SOD activity was decreased in AAA and AAA + DSMO group versus sham group, and AAA + inhibitor could decrease IL-1β, IL-6, IL-10, IL-18, ROS and MDA levels, and increase SOD activity (Fig. 3).